| Target Price | €44.37 |
| Price | €37.34 |
| Potential | 18.85% |
| Number of Estimates | 18 |
| 18 Analysts have issued a price target Qiagen 2026 . The average Qiagen target price is €44.37. This is 18.85% higher than the current stock price. The highest price target is €52.00 39.29% , the lowest is €39.49 5.78% . | |
| A rating was issued by 24 analysts: 12 Analysts recommend Qiagen to buy, 12 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
| Analyst Estimates: Analysts believe that the Qiagen stock has an average upside potential 2026 of 18.85% . Most analysts recommend the Qiagen stock at Buy or hold. |
23 Analysts have issued a sales forecast Qiagen 2025 . The average Qiagen sales estimate is €1.8b . This is 4.11% higher than the revenue of the last 12 months(TTM). The highest sales forecast is €1.9b 8.33% , the lowest is €1.7b 1.98% .
This results in the following potential growth metrics:
| 2024 | €1.7b | 0.66% |
|---|---|---|
| 2025 | €1.8b | 7.37% |
| 2026 | €1.9b | 5.65% |
| 2027 | €2.1b | 6.68% |
| 2028 | €2.3b | 12.45% |
| 2029 | €2.6b | 9.25% |
| 2030 | €2.9b | 14.08% |
22 Analysts have issued an Qiagen EBITDA forecast 2025. The average Qiagen EBITDA estimate is €685m . This is 41.77% higher than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is €764m 58.53% , the lowest is €610m 26.71% .
This results in the following potential growth metrics and future EBITDA Margins:
| 2024 | €437m | 10.64% |
|---|---|---|
| 2025 | €685m | 56.13% |
| 2026 | €736m | 7.50% |
| 2027 | €795m | 8.01% |
| 2028 | €848m | 6.72% |
| 2029 | €905m | 6.75% |
| 2024 | 25.51% | 9.92% |
|---|---|---|
| 2025 | 37.09% | 45.42% |
| 2026 | 37.74% | 1.75% |
| 2027 | 38.21% | 1.25% |
| 2028 | 36.26% | 5.10% |
| 2029 | 35.43% | 2.29% |
24 Qiagen Analysts have issued a net profit forecast 2025. The average Qiagen net profit estimate is €454m . This is 40.08% higher than the net profit for the last 12 months(TTM). The highest net profit forecast is €546m 68.68% , the lowest is €428m 32.16% .
This results in the following potential growth metrics and future Net Margins:
| 2024 | €72.5m | 75.51% |
|---|---|---|
| 2025 | €454m | 525.72% |
| 2026 | €489m | 7.60% |
| 2027 | €535m | 9.35% |
| 2028 | €588m | 10.00% |
| 2029 | €638m | 8.39% |
| 2024 | 4.23% | 75.67% |
|---|---|---|
| 2025 | 24.62% | 482.67% |
| 2026 | 25.08% | 1.87% |
| 2027 | 25.71% | 2.51% |
| 2028 | 25.15% | 2.18% |
| 2029 | 24.95% | 0.80% |
24 Analysts have issued a Qiagen forecast for earnings per share. The average Qiagen EPS is €2.10 . This is 42.86% higher than earnings per share in the financial year 2024. The highest EPS forecast is €2.52 71.43% , the lowest is €1.97 34.01% .
This results in the following potential growth metrics and future valuations:
| 2024 | €0.33 | 75.19% |
|---|---|---|
| 2025 | €2.10 | 536.36% |
| 2026 | €2.26 | 7.62% |
| 2027 | €2.47 | 9.29% |
| 2028 | €2.71 | 9.72% |
| 2029 | €2.94 | 8.49% |
| Current | 25.41 | 77.61% |
|---|---|---|
| 2025 | 17.82 | 29.87% |
| 2026 | 16.56 | 7.07% |
| 2027 | 15.15 | 8.51% |
| 2028 | 13.77 | 9.11% |
| 2029 | 12.70 | 7.77% |
Based on analysts' sales estimates for 2025, the Qiagen stock is valued at an EV/Sales of 4.63 and an P/S ratio of 4.40 .
This results in the following potential growth metrics and future valuations:
| Current | 4.82 | 9.40% |
|---|---|---|
| 2025 | 4.63 | 4.01% |
| 2026 | 4.38 | 5.35% |
| 2027 | 4.10 | 6.27% |
| 2028 | 3.65 | 11.07% |
| 2029 | 3.34 | 8.47% |
| 2030 | 2.93 | 12.34% |
| Current | 4.58 | 10.14% |
|---|---|---|
| 2025 | 4.40 | 3.95% |
| 2026 | 4.16 | 5.35% |
| 2027 | 3.90 | 6.27% |
| 2028 | 3.47 | 11.07% |
| 2029 | 3.17 | 8.47% |
| 2030 | 2.78 | 12.34% |
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Barclays |
Overweight
➜
Overweight
|
Unchanged | Oct 02 2025 |
| UBS |
Neutral
➜
Neutral
|
Unchanged | Aug 07 2025 |
| B of A Securities |
Buy
➜
Buy
|
Unchanged | Jun 26 2025 |
| Barclays |
➜
Overweight
|
Initiated | Jun 24 2025 |
| Baird |
Neutral
➜
Neutral
|
Unchanged | Apr 21 2025 |
| Redburn Atlantic |
Buy
➜
Neutral
|
Downgrade | Apr 04 2025 |
| Baird |
Outperform
➜
Neutral
|
Downgrade | Feb 19 2025 |
| Analyst Rating | Date |
|---|---|
|
Unchanged
Barclays:
Overweight
➜
Overweight
|
Oct 02 2025 |
|
Unchanged
UBS:
Neutral
➜
Neutral
|
Aug 07 2025 |
|
Unchanged
B of A Securities:
Buy
➜
Buy
|
Jun 26 2025 |
|
Initiated
Barclays:
➜
Overweight
|
Jun 24 2025 |
|
Unchanged
Baird:
Neutral
➜
Neutral
|
Apr 21 2025 |
|
Downgrade
Redburn Atlantic:
Buy
➜
Neutral
|
Apr 04 2025 |
|
Downgrade
Baird:
Outperform
➜
Neutral
|
Feb 19 2025 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


